First-Line Capecitabine Monotherapy for Slowly Progressing Metastatic Breast Cancer: Do We Need Aggressive Treatment?

Publisher： Karger

E-ISSN： 1423-0232|77|5|318-327

ISSN： 0030-2414

Source： Oncology, Vol.77, Iss.5, 2009-11, pp. : 318-327

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

First-Line Herceptin^® Monotherapy in Metastatic Breast Cancer

Oncology, Vol. 61, Iss. 2, 2001-10 ,pp. : 37-42

Karger

Access to resources Recommend Favorite

Capecitabine and Vinorelbine as First-Line Treatment in Elderly Patients (≥65 Years) with Metastatic Breast Cancer

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 228-237

Karger

Access to resources Recommend Favorite

Final Results of ERASME-4: A Randomized Trial of First-Line Docetaxel plus either Capecitabine or Epirubicin for Metastatic Breast Cancer

Oncology, Vol. 80, Iss. 3-4, 2011-07 ,pp. : 262-268

Karger

Access to resources Recommend Favorite

Oxaliplatin, Irinotecan and Capecitabine (OCX) for First-Line Treatment of Advanced/Metastatic Colorectal Cancer: A Phase I Trial (SAKK 41/03)

Oncology Research and Treatment, Vol. 33, Iss. 6, 2010-05 ,pp. : 295-299

Karger

Access to resources Recommend Favorite

Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first‐line treatment of patients with advanced breast cancer: Phase 3 randomized trial

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3412-3421

John Wiley & Sons Inc

Access to resources Recommend Favorite